Lupin's Nagpur Facility Gets US FDA VAI Classification for Injectables

• Lupin's Nagpur injectable facility received a Voluntary Action Indicated (VAI) classification from the US FDA.
• The Establishment Inspection Report (EIR) followed an inspection conducted from September 8 to September 16, 2025.
• VAI classification means violations were found but do not warrant further regulatory action, allowing continued drug sales and new approvals.
• Nilesh Gupta, MD, Lupin, affirmed the company's commitment to high quality and compliance standards.
• Lupin shares closed down 0.32% on the BSE after the announcement.

Why It Matters: Lupin's Nagpur injectable facility secured a VAI classification from US FDA, ensuring continued operations.